Ublituximab: all 36 studies that test it

Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression DisorderNot yet recruitingNCT07812181Phase 2
• Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaRecruitingNCT07680946Phase 2
• A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)RecruitingNCT07673744Phase 2
• Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple SclerosisRecruitingNCT07389590Phase 4
• Ublituximab (Briumvi) for Early Forms of Relapsing Multiple SclerosisRecruitingNCT07225361Phase 4
• Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisRecruitingNCT07220252Phase 2/3
• Ublituximab in Autoantibody Positive Immune Mediated Necrotizing MyopathyRecruitingNCT07103746Phase 2
• Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple SclerosisRecruitingNCT06864936Not applicable
• Effects of Ublituximab on Motor Functions in Multiple SclerosisRecruitingNCT06629428Early Phase 1
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabRecruitingNCT05877963Phase 3
• Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04783415Phase 2Results posted
• Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)TerminatedNCT04692155Phase 1/2Results posted
• Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLActive, not recruitingNCT04624633Phase 2Results posted
• Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel TherapyTerminatedNCT04149821Phase 2Results posted
• Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaTerminatedNCT03828448Phase 2Results posted
• Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )CompletedNCT03277261Phase 3Results posted
• Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)CompletedNCT03277248Phase 3Results posted
• Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple SclerosisCompletedNCT02738775Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304TerminatedNCT02656303Phase 2Results posted
• Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT02612311Phase 3Results posted
• Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)CompletedNCT02301156Phase 3Results posted
• Ublituximab for Acute Neuromyelitis Optica (NMO) RelapsesCompletedNCT02276963Phase 1Results posted
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT07211633Phase 3
• Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular LymphomaWithdrawnNCT05152459Phase 1/2
• Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT04806035Phase 1
• Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaWithdrawnNCT04635683Phase 1
• An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisActive, not recruitingNCT04130997Phase 3
• An Extension of the TG1101-RMS201 TrialCompletedNCT03381170Phase 2
• Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 TrialsTerminatedNCT03207256Phase 2
• Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaTerminatedNCT02793583Phase 2/3
• Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's TransformationCompletedNCT02535286Phase 1
• Ublituximab + Ibrutinib in Select B-cell MalignanciesCompletedNCT02013128Phase 1/2
• Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell MalignanciesCompletedNCT02006485Phase 1
• Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid MalignanciesTerminatedNCT01744912Phase 1
• Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT01647971Phase 1/2
• LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic LeukemiaCompletedNCT01098188Phase 1

← Ublituximab overview